Fabrication of ethosuximide loaded alginate/polyethylene oxide scaffolds for epilepsy research using 3D-printing method

• Published in: Frontiers in bioengineering and biotechnology 2023-12, Vol.11, p.1244323-1244323
• Main Authors: Karabulut, Hatice, Dutta, Abir, Moukbil, Yunis, Cisen Akyol, Aysim, Ulag, Songul, Aydin, Banu, Gulhan, Rezzan, Us, Zeynep, Kalaskar, Deepak M, Gunduz, Oguzhan
• Format: Article
• Language: English
• Subjects: 3D-printing; drug resistant epilepsy; epilepsy treatment; implantable scaffolds; polyethylene oxide; sodium alginate
• ISSN: 2296-4185; 2296-4185
• DOI: 10.3389/fbioe.2023.1244323

Epilepsy is a medical condition that causes seizures and impairs the mental and physical activities of patients. Unfortunately, over one-third of patients do not receive adequate relief from oral Antiepileptic Drugs (AEDs) and continue to experience seizures. In addition to that, long term usage of Antiepileptic Drugs can cause a range of side effects. To overcome this problem, the precision of 3D printing technology is combined with the controlled release capabilities of biodegradable polymers, allowing for tailored and localized AED delivery to specific seizure sites. As a result of this novel technique, therapeutic outcomes can be enhanced, side effects of AEDs are minimized, and patient-specific dosage forms can be created. This study focused on the use of ethosuximide, an antiepileptic drug, at different concentrations (10, 13, and 15 mg) loaded into 3D-printed sodium alginate and polyethylene oxide scaffolds. The scaffolds contained varying concentrations (0.25%, 0.50%, and 0.75% w/v) and had varying pores created by 3D patterning sizes from 159.86 ± 19.9 µm to 240.29 ± 10.7 µm to optimize the releasing system for an intracranial administration. The addition of PEO changed the T and T temperatures from 65°C to 69°C and from 262°C to 267°C, respectively. Cytotoxicity assays using the human neuroblastoma cell line (SH-SY5Y) showed that cell metabolic activity reached 130% after 168 h, allowing the cells to develop into mature neural cells. testing demonstrated sustained ethosuximide release lasting 2 hours despite crosslinking with 3% CaCl . The workpaves the way for the use of ethosuximide -loaded scaffolds for treating epilepsy.